The role of SGLT2 inhibitors in managing Type 2 Diabetes

Research output: Contribution to journalArticlepeer-review


The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.
Original languageAmerican English
StatePublished - Jun 2018


  • Diabetes
  • SGLT2 Inhibitors
  • Type 2 Diabetes


  • Medicine and Health Sciences

Cite this